Adial Pharmaceuticals, Inc. (ADIL)Healthcare | Biotechnology | Glen Allen, United States | NasdaqCM
2.83 USD
+0.05
(1.799%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 2.77 -0.06 (-0.060%) ⇩ (July 13, 2026, 7:44 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 4:10 a.m. EDT
The immediate outlook is bearish due to a severe multi-year structural decline. Despite recent price action showing a temporary bounce off lows, the underlying business has suffered five consecutive years of negative annual returns, with the trailing four years being a relentless downward spiral. This trajectory suggests the market has permanently repriced the company's prospects, rendering any short-term technical recovery fragile. Fundamentally, the situation is dire: the company reports negative earnings, negative free cash flow, and negative returns on both assets and equity, indicating a business that is currently destroying capital rather than generating it. While recent headlines highlight a $64 million financing round and a new drug pipeline, these developments are insufficient to offset the deep value gap created by years of performance failure. Furthermore, the lack of analyst coverage and the absence of any dividend history confirm that this is a speculative vehicle with no income floor. Investors should view the recent rally with skepticism, as the core fundamentals remain broken. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.366786 |
| MSTL_90 | 0.404101 |
| MSTL_52_90 | 0.419189 |
| MSTL | 0.443178 |
| AutoETS | 0.448375 |
| AutoARIMA | 0.448706 |
| MSTL_52 | 0.503178 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 22% |
| H-stat | 331.80 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.035 |
| Excess Kurtosis | -1.62 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 6,193,367 |
| Forward P/E | -0.20 |
| Beta | 1.43 |
| Website | https://www.adial.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.69945943 |
| Address1 | 4,870 Sadler Road |
| Address2 | Suite 300 |
| All Time High | 5,900.0 |
| All Time Low | 1.31 |
| Ask | 2.87 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 46,970 |
| Average Daily Volume3 Month | 479,386 |
| Average Volume | 479,386 |
| Average Volume10Days | 46,970 |
| Beta | 1.432 |
| Bid | 2.77 |
| Bid Size | 12 |
| Book Value | 2.463 |
| City | Glen Allen |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.83 |
| Current Ratio | 3.181 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 2.9398 |
| Day Low | 2.71 |
| Display Name | Adial Pharmaceuticals |
| Earnings Timestamp End | 1,755,288,000 |
| Earnings Timestamp Start | 1,754,942,400 |
| Ebitda | -7,549,321 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.196 |
| Enterprise Value | 1,482,347 |
| Eps Forward | -14.25 |
| Eps Trailing Twelve Months | -5.01 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.2426 |
| Fifty Day Average Change | 0.58739996 |
| Fifty Day Average Change Percent | 0.2619281 |
| Fifty Two Week Change Percent | -69.945946 |
| Fifty Two Week High | 19.0 |
| Fifty Two Week High Change | -16.17 |
| Fifty Two Week High Change Percent | -0.85105264 |
| Fifty Two Week Low | 1.31 |
| Fifty Two Week Low Change | 1.52 |
| Fifty Two Week Low Change Percent | 1.1603054 |
| Fifty Two Week Range | 1.31 - 19.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,532,698,200,000 |
| Float Shares | 1,418,798 |
| Forward Eps | -14.25 |
| Forward P E | -0.19859649 |
| Free Cashflow | -3,900,587 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 5 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.04322 |
| Held Percent Institutions | 0.2743 |
| Implied Shares Outstanding | 2,188,469 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,770,336,000 |
| Last Split Factor | 1:25 |
| Long Business Summary | Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia. |
| Long Name | Adial Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 6,193,367 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_112638788 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -7,770,762 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 6,040,174 |
| Number Of Analyst Opinions | 2 |
| Open | 2.79 |
| Operating Cashflow | -6,519,611 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 804 487 8196 |
| Post Market Change | -0.059999943 |
| Post Market Change Percent | -2.1201394 |
| Post Market Price | 2.77 |
| Post Market Time | 1,783,986,243 |
| Previous Close | 2.78 |
| Price Hint | 4 |
| Price To Book | 1.1490052 |
| Profit Margins | 0.0 |
| Quick Ratio | 3.036 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.05 |
| Regular Market Change Percent | 1.79856 |
| Regular Market Day High | 2.9398 |
| Regular Market Day Low | 2.71 |
| Regular Market Day Range | 2.71 - 2.9398 |
| Regular Market Open | 2.79 |
| Regular Market Previous Close | 2.78 |
| Regular Market Price | 2.83 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 52,663 |
| Return On Assets | -1.08745 |
| Return On Equity | -2.65944 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 2,188,469 |
| Shares Percent Shares Out | 0.105500005 |
| Shares Short | 230,979 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 47,293 |
| Short Name | Adial Pharmaceuticals, Inc |
| Short Percent Of Float | 0.10609999 |
| Short Ratio | 0.21 |
| Source Interval | 15 |
| State | VA |
| Symbol | ADIL |
| Target High Price | 8.0 |
| Target Low Price | 6.0 |
| Target Mean Price | 7.0 |
| Target Median Price | 7.0 |
| Total Cash | 4,584,100 |
| Total Cash Per Share | 2.138 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -5.01 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.6354 |
| Two Hundred Day Average Change | -1.8053999 |
| Two Hundred Day Average Change Percent | -0.38948095 |
| Type Disp | Equity |
| Volume | 52,663 |
| Website | https://www.adial.com |
| Zip | 23,060 |